Romidepsin Induces Complete Response in Peripheral T-Cell Lymphoma

Gloucester Pharmaceuticals sponsored the trial. Dr. Coiffier is a consultant to, and has received honoraria from, Gloucester. He has similar relationships with Celgene, which acquired Gloucester 2010; he also declared research funding from Celgene and has served on its speakers bureau. Most of his coauthors had relationships with Celgene and/or Gloucester, and two were Celgene employees. The trial involved off-label use of romidepsin.